What did @manuelenriqueee actually say?
The creator ran a 50-day self-experiment using three peptides, at minimum GHK-Cu and CJC-1295, to test skin improvement, scar reduction, and physique changes. He tracked baseline strength at 100-lb dumbbells for five reps and photographed his skin. He later admitted he had been co-injecting GHK-Cu and CJC-1295 for 21 days, calling it a mistake because "the effects aren't gonna be as good." He ran out of GHK-Cu on day 24, had delivery delays, and then started doing something unspecified that he "wasn't supposed to do." The full results are only on YouTube, meaning this TikTok at 410K views is a highlight reel of protocol errors, not a documented transformation.
Does the science back this up?
Weakly, and mostly in preclinical settings. GHK-Cu has legitimate research behind it for skin remodeling. Pickart and Margolina (2018, Cosmetics) reviewed evidence that copper-peptide complexes stimulate collagen and glycosaminoglycan synthesis in vitro and in animal models. That is not the same as injecting synthetic GHK-Cu subcutaneously and watching scars disappear in 50 days on a human. CJC-1295 is a growth hormone-releasing hormone analogue. Studies like Teichman et al. (2006, Journal of Clinical Endocrinology and Metabolism) showed sustained GH elevation in healthy adults, but the subjects were not gym-goers chasing physique changes. No peer-reviewed trial has mapped CJC-1295 use to the kind of body composition changes implied here. The claim that co-injecting these two peptides reduces efficacy has no published pharmacokinetic basis that this writer could locate.
- GHK-Cu skin data: mostly in vitro or animal models, not 50-day subcutaneous human trials
- CJC-1295 GH elevation: documented in clinical settings, physique outcomes are not
- The "don't stack these two" rule: circulates in bodybuilding forums, not peer-reviewed literature
What did they get wrong (or right)?
He got the skeptical framing right. Saying he "never seen an actual transformation documented before" is a fair criticism of peptide content online, and attempting any kind of self-tracking is better than zero. Credit there. But the experiment has serious methodological problems. A single subject with no control condition, no blinded assessment, changing protocols mid-study, running out of a compound, and then doing something unspecified to "make up for missed days" is not an experiment. It is a personal diary. The claim that simultaneous GHK-Cu and CJC-1295 injection reduces efficacy is repeated confidently but sourced nowhere in the video. This matters because viewers may restructure their own protocols based on a claim with no traceable evidence. The unspecified thing he "wasn't supposed to do" is a genuine safety flag. Increasing doses or injection frequency of peptides that affect growth hormone secretion without clinical supervision carries real risk, including potential effects on insulin sensitivity and IGF-1 levels.
What should you actually know?
These peptides are not approved by the FDA for the uses described here. GHK-Cu appears in some topical cosmetic formulations where it has a longer safety record, but subcutaneous injection is a different route with different pharmacokinetics and no established dosing safety data in healthy humans outside clinical trials. CJC-1295 is not an approved drug. It is available as a research chemical and through some compounding pharmacies, but compounded peptides are not equivalent to pharmaceutical-grade products with validated manufacturing standards. Anyone seeing this video and thinking about replicating it should know that the creator changed his protocol three times, admitted errors, and withheld the actual outcome behind a YouTube link. That is not a clean data set. A physician specializing in endocrinology or sports medicine is the right starting point before anyone injects a growth hormone secretagogue, not a TikTok experiment with 50 days and shifting variables.
- GHK-Cu: some topical safety data exists, subcutaneous injection in healthy humans is not well-studied
- CJC-1295: affects the GH-IGF-1 axis, not something to self-administer without baseline labs
- Protocol changes mid-experiment invalidate before-after comparisons
- "Making up for missed days" by doing something unsanctioned suggests dose escalation, which is a risk